BNR
Burning Rock Biotech Limited
NASDAQ · Healthcare · Medical - Diagnostics & Research · CN
$11.03
+2.32%Year over year
Reported trailing growth
- Revenue
- -1.7%
- EBITDA
- +87.0%
- EBIT
- +76.3%
- EPS
- +75.6%
- Free cash flow
- +51.3%
- Operating cash flow
- +54.7%
Forward estimates
Based on analyst estimates
- Revenue
- +11.9%
- EBITDA
- +24.3%
- EPS
- -20.4%
Three-year CAGR
- Revenue
- -1.4%
- EBITDA
- +88.2%
- EBIT
- +84.7%
- Net income
- +84.0%
- EPS
- -47.3%
- Free cash flow
- +65.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026